Elan Corporation
Latest Elan Corporation News
-
J&J takes on Alzheimer's disease with $1B stake in Elan
biopharmaceutical company Elan , investing reinvigorate ailing Elan eln and save the jobs more money than Elan into the research 4% stake in Elan by spending low as $5. Elan , which sells Tysabri for multiple sclerosis and Prialt for severe pain
-
Tysabri May Treat Myelin Sheath Damage From MS
HealthDay News) -- The drug Tysabri (natalizumab) appears makers Biogen Idec and Elan Corp shows. MS is nervous system patients who took either Tysabri , interferon beta-1a the 62 patients who took Tysabri showed remyelination when
-
Health Highlights: August 3, 2008
reported among users of Tysabri , a multiple sclerosis international concern about Tysabri and its connection with Biogen and co-maker Elan Corp , based in Ireland, voluntarily withdrew Tysabri in February 2005 after
-
Stocks drop on jobs data, close the week mixed; oil rises on Iran fears
sell-offs on Friday. Biogen Idec and Elan fell due to safety concerns related to multiple sclerosis therapy Tysabri . Biogen dropped $19.75, or 28%, to $50.01, and Elan tumbled $10.12, or 50%, to $9
-
Health Highlights: August 2, 2008
reported among users of Tysabri , a multiple sclerosis international concern about Tysabri and its connection with Biogen and co-maker Elan Corp , based in Ireland, voluntarily withdrew Tysabri in February 2005 after
-
Health Highlights: August 1, 2008
reported among users of Tysabri , a multiple sclerosis international concern about Tysabri and its connection with Biogen and co-maker Elan Corp , based in Ireland, voluntarily withdrew Tysabri in February 2005 after
News
-
Health Highlights: July 30, 2008
says a study presented Tuesday at the International Conference on Alzheimer's Disease in Chicago. The drug, made by Elan Corp and Wyeth, did slow memory loss in some patients better than existing treatments, but it had no effect in people with
-
Health Highlights: June 17, 2008
study results released Tuesday by drug makers Wyeth and Elan Corp , the Wall Street Journal reported. In patients with a expected that it will be at least two years before Wyeth and Elan apply for FDA approval of bapineuzumab, the Wall Street
-
Tysabri May Cause Liver Damage, Health Officials Say
Administration expanded the use of Tysabri to treat Crohn's disease granted approval to use Tysabri for Crohn's disease Cambridge, Mass., and Elan Corp . -- to send letters to warning about the danger of Tysabri to the liver is already
-
Tysabri Approved for Crohn's Disease
15 (HealthDay News) -- Tysabri (natalizumab) has been responded to other therapies. Tysabri , made by the Ireland-based drugmaker Elan and Massachusetts-based called Crohn's Disease- Tysabri Outreach Unified Commitment
-
Health Highlights: May 22, 2007
Two drug companies are seeking approval to launch advanced Phase III trials of a drug to fight Alzheimer's disease. Elan Corp . PLC of Ireland and Wyeth of the United States hope the drug bapineuzumab will prove successful at halting Alzheimer's-related
-
Biogen Idec exploring potential sale
withdrew a newer MS drug called Tysabri in February 2005 because of safety concerns. Tysabri had been seen as a potential Biogen Idec and Irish partner Elan before it was withdrawn European authorities approved Tysabri 's reintroduction in June
-
New Hope for MS Patients?
Tysabri , a medication that treats patients were so interested in Tysabri , which came on the market was sold by Biogen Idec and Elan Pharmaceuticals. Clinical the manufacturers removed Tysabri from the market so the risks
